• Company
• Zerbaxa on the verge of entering insurance benefits in 5 yrs
• by Eo, Yun-Ho Aug 26, 2022 05:35am

• Company
• First patient dosed with Yuhan’s degenerative disc drug
• by Aug 26, 2022 05:35am

• Policy
• Pts with osteopenia need screening tx
• by Kim, Jung-Ju Aug 26, 2022 05:35am

• Policy
• MET mutant anticancer drug Tepmetko challenges
• by Lee, Tak-Sun Aug 25, 2022 05:52am

• Policy
• Entry of HER2-low breast cancer Tx imminent in Korea
• by Lee, Hye-Kyung Aug 25, 2022 05:52am

• Policy
• 3rd gen ALK NSCLC drug Lorviqua to be listed on next month
• by Lee, Tak-Sun Aug 25, 2022 05:52am

• Company
• LG Chem Life Science achieves new quarterly sales record
• by Kim, Jin-Gu Aug 25, 2022 05:52am

• Policy
• Benefit for Sigmart 48mg will be newly established on Sept.
• by Kim, Jung-Ju Aug 25, 2022 05:52am

• Policy
• All domestic restrictions on PVA cut are agreed
• by Lee, Tak-Sun Aug 24, 2022 05:56am

• Opinion
• [Reporter’s View] Unresolved insulin cold chain issue
• by Aug 24, 2022 05:56am